What is the appropriate workup and management for a patient with anemia of chronic disease and left‑shift leukocytosis?

Workup and Management of Anemia of Chronic Disease with Left-Shift Leukocytosis

The left-shift leukocytosis indicates active inflammation or infection that is likely driving the anemia of chronic disease, so your immediate priority is identifying and treating the underlying inflammatory/infectious process while simultaneously evaluating iron status to guide anemia management.

Initial Diagnostic Workup

Essential Laboratory Parameters

Obtain the following to distinguish anemia of chronic disease (ACD) from iron deficiency and guide treatment 1, 2, 3:

• Complete blood count with differential - The left shift (increased band forms/immature neutrophils) confirms active inflammation or infection
• Iron studies: serum ferritin, transferrin saturation (TSAT), serum iron
• Inflammatory markers: CRP, ESR
• Reticulocyte count - Low or inappropriately normal reticulocytes indicate impaired erythropoiesis
• Mean corpuscular volume (MCV) and red cell distribution width (RDW)

Diagnostic Criteria for ACD vs Iron Deficiency

In the presence of inflammation (elevated CRP/leukocytosis):

• Pure ACD: Ferritin >100 μg/L AND transferrin saturation <20% 1, 2, 3
• Iron deficiency: Ferritin <30 μg/L (or <100 μg/L with inflammation) 1, 3
• Mixed picture: Ferritin 30-100 μg/L suggests both iron deficiency and ACD coexist 2, 3

Critical caveat: Ferritin is an acute phase reactant and can be falsely elevated by inflammation. In inflammatory states, ferritin up to 100 μg/L may still reflect true iron deficiency 1.

Identify the Underlying Cause

The left-shift leukocytosis demands investigation for:

Infectious Causes

• Blood cultures, urinalysis/culture
• Chest imaging if respiratory symptoms
• Consider occult abscesses or endocarditis in appropriate clinical context

Inflammatory/Autoimmune Conditions

• Inflammatory bowel disease: Consider if GI symptoms present - may need endoscopy 2, 1
• Rheumatoid arthritis or other connective tissue diseases
• Chronic kidney disease: Check creatinine, eGFR 4, 5
• Chronic heart failure: Assess cardiac function 6
• Malignancy: Age-appropriate cancer screening

Additional Workup if Cause Unclear

• Vitamin B12 and folate levels (macrocytosis suggests deficiency) 2, 1
• Haptoglobin, LDH, bilirubin if hemolysis suspected (elevated reticulocytes) 2
• Consider bone marrow examination only if diagnosis remains unclear after comprehensive workup 2

Management Strategy

1. Treat the Underlying Inflammatory/Infectious Process

This is paramount - ACD results from cytokine-mediated hepcidin elevation that blocks iron absorption and sequesters iron in macrophages 7, 8, 9. The anemia will not fully resolve without controlling the underlying disease.

2. Iron Supplementation

For patients with true iron deficiency (ferritin <30-100 μg/L):

• Intravenous iron is preferred over oral iron in the setting of inflammation 10, 1
  • Oral iron is poorly absorbed due to hepcidin-induced blockade of intestinal iron uptake 10, 7, 8
  • IV iron overcomes hepcidin-mediated iron restriction 10
  • Oral iron causes significant GI side effects and is frequently discontinued 1

Specific recommendations by condition:

• IBD: Oral iron ≤100 mg elemental iron daily; IV iron if Hb <100 g/L or oral intolerance 1
• Chronic heart failure: IV iron preferred; avoid oral iron due to gut edema and poor absorption 1, 6, 1
• CKD: IV iron preferred, especially for hemodialysis patients 4, 5

Do NOT give iron alone in pure ACD (ferritin >100 μg/L, TSAT <20%) without erythropoietin therapy, as iron promotes microbial growth and may worsen outcomes 11.

3. Erythropoiesis-Stimulating Agents (ESAs)

Indications for ESA therapy:

• Hemoglobin <100 g/L (10 g/dL) with symptomatic anemia 5, 12
• After correcting iron deficiency and treating reversible causes 12
• Particularly beneficial in CKD, cancer-related anemia, and chronic inflammatory conditions 4, 5, 12

Target hemoglobin: 100-120 g/L (10-12 g/dL) 5, 12

• Avoid targeting >130 g/L due to cardiovascular risks 5

Administration:

• Subcutaneous route is more efficient than IV (requires 15-50% lower doses) 4
• Start 2-3 times weekly; may transition to weekly once stable 4

ESA therapy often requires concurrent IV iron in inflammatory states to overcome functional iron deficiency and improve response 10, 13.

4. Red Blood Cell Transfusion

Transfusion should be avoided when possible 5:

• Increases allosensitization risk (problematic for transplant candidates) 5
• Does not address underlying pathophysiology 13

Reserve transfusion for:

• Symptomatic anemia causing hemodynamic instability 5
• Acute hemorrhage 5
• Urgent preoperative correction 5
• Do not transfuse based solely on hemoglobin threshold - base decision on symptoms 5

Monitoring

• Hemoglobin: Every 3 months for CKD stage 3-5 not on dialysis; monthly for dialysis patients 5
• Iron studies: Reassess after treatment and periodically to detect recurrence 1
• Inflammatory markers: Track CRP/ESR to assess disease activity
• White blood cell count: Resolution of left shift indicates improving inflammation

Common Pitfalls to Avoid

1. Assuming elevated ferritin excludes iron deficiency - In inflammation, ferritin up to 100 μg/L may still indicate iron deficiency 1, 3
2. Using oral iron in inflammatory states - Hepcidin blocks absorption; use IV iron 10, 1
3. Transfusing chronic anemia without addressing underlying cause - This provides only temporary relief 5, 13
4. Ignoring the left shift - This signals active inflammation requiring investigation and treatment
5. Starting ESAs without correcting iron deficiency first - ESAs are ineffective with inadequate iron stores 12